|Bid||60.00 x 100|
|Ask||63.99 x 200|
|Day's Range||60.12 - 60.73|
|52 Week Range||53.06 - 65.20|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.14%|
Incorporated in Delaware, Arrowhead Pharmaceuticals (ARWR) is focused on developing medicines for treating intractable diseases by silencing the genes that cause them. The therapies developed by Arrowhead make use of a broad portfolio of RNA chemistries and efficient modes of delivery to trigger an RNA interference mechanism that induces the rapid and durable knockdown of the target genes. RNA interference or (RNAi) is a mechanism that inhibits the expression of a specific gene.
The Federal Reserve hiked interest rates three times last year and more rate increases are expected this year. Still, 10-year Treasuries yield less than 2.7%, underscoring a nearly four-decade downtrend in U.S. borrowing costs. For its part, the S&P 500 yields an anemic 1.8%.
Learning how Harvard, Stanford and Yale invest billions could help the average individual investor with their portfolio
The biggest bargains for real estate investors are in hot surging markets in Europe and Asia, where home prices are lower.
Perspective from Franklin Templeton Fixed Income Group® In This Issue: Broader Growth Across US Economy Provides Solid Backdrop for Further Interest-Rate Hikes Recent signs of a better balance to the growth seen across the US economy strengthen the ...
Globally, real estate investment trusts (REITs) have become a popular way for investors to invest in property while at the same time receiving an income. This is particularly true in Singapore, which has developed into a hub for REITs in Asia ever ...